Theralase commences equity financing oct 2012
Upcoming SlideShare
Loading in...5
×
 

Theralase commences equity financing oct 2012

on

  • 214 views

Private Placement

Private Placement

Statistics

Views

Total Views
214
Slideshare-icon Views on SlideShare
213
Embed Views
1

Actions

Likes
0
Downloads
0
Comments
0

1 Embed 1

http://www.twylah.com 1

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Theralase commences equity financing oct 2012 Theralase commences equity financing oct 2012 Document Transcript

    • Press Release Theralase Commences Equity FinancingTORONTO, ONTARIO-- Oct. 4, 2011 - Theralase Technologies Inc. (TSX-V:TLT) announced today that ithas commenced raising funds from accredited investors in a non-brokered private placement (the"Private Placement") of up to 2,000,000 units (the "Units") at a price of CND $0.25 per Unit for grossproceeds of up to CDN $500,000.00. Each Unit consists of one common share in the capital of theCompany and one-half of one non- transferable common share purchase warrant (a "Warrant"). Eachwhole Warrant entitles the holder to purchase one additional common share (a "Warrant Share") inthe capital of the Company for 1 year after closing at a price of CDN $0.38 per Warrant Share. Thesecurities issued under the Private Placement including any shares issued upon exercise of theWarrants are subject to a four month holding period, commencing upon closing.The company intends to utilize the proceeds of the Private Placement to provide additional workingcapital to further develop the Companys prospects in a number of areas, specifically: • Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network • Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of cancers, bacteria and viruses • TLC-1000 therapeutic medical laser USA sales and marketing expansion • TLC-2000 therapeutic medical biofeedback laser commercializationAbout Theralase Technologies Inc.:Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented,superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralasetechnology is safe and effective in treating pain, inflammation and for tissue regeneration of neuralmuscular skeletal conditions and wound healing in both humans and animals. Theralase complies withall FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and highquality products. Theralase also develops patented Photo Dynamic Compound (PDC) technologyfocused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’sproprietary and patented laser technologies.For further information please visit www.theralase.com, regulatory filings may be viewed by visitingwww.sedar.com.This press release contains forward-looking statements, which reflect the Companys current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation toupdate these forward-looking statements.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) acceptsresponsibility for the adequacy or accuracy of this release.For More Information, please contact:Roger Dumoulin-White,President and CEO416-447-8455 ext. 225rwhite@theralase.com
    • Press ReleaseKristina HacheyChief Financial Officer416-447-8455 ext. 224khachey@theralase.comGreg BewshDirector of Investor Relations416-447-8455 ext. 262gbewsh@theralase.com